Dermatitis

ANAPTYSBIO ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AnaptysBio, Inc. and Encourages Investors to Contact the Firm

Thursday, March 26, 2020 - 10:39pm

Investors have until May 26, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 26, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • During the Class Period, the Companys lead asset was etokimab (formerly ANB020), a drug intended for the treatment of various inflammatory diseases.
  • On October 10, 2017the first day of the Class Periodthe Company reported data from an interim analysis of its Phase 2a clinical trial of etokimab in atopic dermatitis.
  • As a result of Defendants' misrepresentations, shares of AnaptysBio common stock traded at artificially inflated prices throughout the Class Period.

Global Chronic Hand Eczema (CHE) Markets, Epidemiology, Drugs, Pipeline and Forecast to 2030

Tuesday, March 24, 2020 - 2:15pm

The total prevalent cases of Chronic Hand Eczema (CHE) in the 7MM was found to be 4,229,215 in 2017.

Key Points: 
  • The total prevalent cases of Chronic Hand Eczema (CHE) in the 7MM was found to be 4,229,215 in 2017.
  • The prevalence of Chronic Hand Eczema (CHE) in the 7MM is expected to increase during the study period of 2017-2030.
  • The epidemiology has segmented into Total Prevalent cases of Chronic Hand Eczema, Gender-Specific cases of Chronic Hand Eczema, Diagnosed Cases of Chronic Hand Eczema, and Age-Specific cases of Chronic Hand Eczema, Severity Specific Cases of Chronic Hand Eczema and Subgroup Specific Cases of Chronic Hand Eczema.
  • Chronic Hand Eczema is estimated to occur in 5-7% of patients with Hand Eczema.

Kindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in Dogs

Tuesday, March 24, 2020 - 12:31pm

The study was a randomized, blinded, placebo-controlled pilot effectiveness study that enrolled 26 client-owned dogs diagnosed with atopic dermatitis to assess the efficacy, safety, and pharmacokinetic profile of KIND-025.

Key Points: 
  • The study was a randomized, blinded, placebo-controlled pilot effectiveness study that enrolled 26 client-owned dogs diagnosed with atopic dermatitis to assess the efficacy, safety, and pharmacokinetic profile of KIND-025.
  • Treatment success for individual dogs at each visit was defined as a 50% or higher reduction from baseline in CADESI-4 or PVAS scores.
  • Positive efficacy signals were also detected with other endpoints including 20mm or higher reduction from baseline in PVAS score.
  • "These positive results mark KindredBio's eighth positive pilot study in a row, half of which relate to canine dermatitis.

Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis

Tuesday, March 24, 2020 - 12:00pm

The global AD treatment market is set to witness healthy growth, with forecasts ranging up to USD $18.3 billion by 2027.

Key Points: 
  • The global AD treatment market is set to witness healthy growth, with forecasts ranging up to USD $18.3 billion by 2027.
  • There is still a significant unmet need in the treatment of atopic dermatitis, especially in pediatric atopic dermatitis, where AD effects 15% to 20% of children.
  • Derm-Biome CSO Dr. Poul Sorensen: Inflammation is a major contributor to physical health problems and chronic diseases such as atopic dermatitis.
  • The results of a Skin Tolerability and Pharmacokinetics Study in swine showed that the compound was well tolerated.

U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis

Tuesday, March 24, 2020 - 10:45am

"The approval of a steroid-free treatment option for this age group offers potential relief for these very young patients."

Key Points: 
  • "The approval of a steroid-free treatment option for this age group offers potential relief for these very young patients."
  • EUCRISA may cause side effects including allergic reactions at or near the application site.
  • EUCRISA is a prescription ointment used on the skin (topical) to treat mild-to-moderate eczema (atopic dermatitis) in adults and pediatric patients 3 months of age and older.
  • 2Pfizer Inc. Pfizer Receives FDA Approval for EUCRISA (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema).

 Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch

Wednesday, March 18, 2020 - 8:15pm

Dupilumab, the active control on these primary endpoints, demonstrated superiority to placebo at Week 12 and Week 16.

Key Points: 
  • Dupilumab, the active control on these primary endpoints, demonstrated superiority to placebo at Week 12 and Week 16.
  • Safety results showed that a larger percentage of patients receiving abrocitinib 200mg experienced adverse events (61.9%) than in other treatment arms.
  • The percentages of patients experiencing adverse events were similar for placebo (53.4%), abrocitinib 100mg (50.8%), and dupilumab (50%).
  • The study was the third trial in the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program for abrocitinib.

New Eczema Report Depicts Enormous Burdens and Huge Unmet Medical Needs

Wednesday, March 18, 2020 - 3:00pm

More than 33 million Americans of all ages experience eczema, an inflammatory skin disease that results in rashes and patches of itchy, red skin.

Key Points: 
  • More than 33 million Americans of all ages experience eczema, an inflammatory skin disease that results in rashes and patches of itchy, red skin.
  • Kenneth Mendez, President & CEO of the Asthma and Allergy Foundation of America, remarked on the huge unmet need for safer, more effective treatments this initiative revealed.
  • Meeting participants, many of whom are quoted directly in the report, expressed a desire for more targeted approaches to therapy.
  • Founded in 1988, the National Eczema Association (NEA) works to improve the health and quality of life for individuals with eczema through research, support, and education.

Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis

Monday, March 16, 2020 - 12:37pm

As no cure for psoriasis exists, patients and dermatologists need new and better topical treatment options to manage this chronic inflammatory condition.

Key Points: 
  • As no cure for psoriasis exists, patients and dermatologists need new and better topical treatment options to manage this chronic inflammatory condition.
  • Based on its safety, tolerability and efficacy profile in our completed clinical trials, we believe topical roflumilast has the potential to be both the best-in-class topical PDE4 inhibitor and the only topical PDE4 inhibitor approved for plaque psoriasis, including in children."
  • Arcutis is currently conducting a Phase 3 clinical program with topical roflumilast cream, including two ongoing Phase 3 clinical trials (Studies ARQ-151-301 and ARQ-151-302) to support registration with the FDA.
  • Arcutis is currently developing three novel compounds (topical roflumilast cream, topical roflumilast foam and ARQ-252) for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema.

Asana BioSciences Announces Topical Sodium Channel Blocker ASN008 Achieves Positive Results for the Treatment of Pruritus in Atopic Dermatitis; and Provides Update on JAK/SYK Inhibitor Gusacitinib in Phase 2 Studies for Chronic Hand Eczema and AD

Tuesday, March 10, 2020 - 11:00am

Asana BioSciences announced today positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis (NCT03798561) for its topical sodium channel blocker, ASN008.

Key Points: 
  • Asana BioSciences announced today positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis (NCT03798561) for its topical sodium channel blocker, ASN008.
  • ASN008 demonstrated low systemic exposure, and safety results show that it was well tolerated with only mild adverse events.
  • We are excited by these clinical data which provide proof-of-concept for ASN008 in the treatment of pruritus associated with atopic dermatitis.
  • Asana is also developing an oral Janus kinase (JAK) and Spleen tyrosine kinase (SYK) inhibitor, gusacitinib, for immunology/dermatology indications such as chronic hand eczema and atopic dermatitis.

NEA and PeDRA Announce 2020 Childhood Eczema Challenge Grant

Thursday, March 5, 2020 - 3:15pm

NOVATO, Calif., March 5, 2020 /PRNewswire/ --The National Eczema Association (NEA) and the Pediatric Dermatology Research Alliance (PeDRA) announce their collaboration in creating the first-of-its-kindChildhood Eczema Challenge Grant to accelerate research that improves the health and quality of life of pediatric patients and their families.

Key Points: 
  • NOVATO, Calif., March 5, 2020 /PRNewswire/ --The National Eczema Association (NEA) and the Pediatric Dermatology Research Alliance (PeDRA) announce their collaboration in creating the first-of-its-kindChildhood Eczema Challenge Grant to accelerate research that improves the health and quality of life of pediatric patients and their families.
  • The Childhood Eczema Challenge Grant will focus on at least one of four research areas: novel insights into disease heterogeneity, innovation in clinical practice and care, understanding and alleviating disease burden, and eczema prevention.
  • "By collaborating with NEA on this Challenge Grant, we expect to answer questions that matter to patients and caregivers," says Michael Siegel, PhD, executive director of PeDRA.
  • Applications for the Challenge Grant are due by May 1, 2020, with the awardee to be announced by June 30, 2020.